Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alloantigen administration before transplantation, either alone or in combination with therapeutic agents that modulate the functional activity of the responding leukocytes, can be a powerful way of inducing specific unresponsiveness to alloantigens in vivo. In theory, any cell expressing one or more donor alloantigens has the ability to modulate the subsequent immune response to an allograft expressing the same molecules. However, not all sources of cells are equal in their ability to induce specific unresponsiveness. Understanding the molecular mechanisms that influence the way the outcome of the immune response to alloantigen develops, either activation or unresponsiveness to the triggering antigen, will enable the immune system to be manipulated more effectively for therapeutic purposes.


Journal article



Publication Date





S16 - S18


Animals, Antibodies, Monoclonal, CD4 Antigens, Cell Transplantation, Graft Survival, Humans, Immune System, Isoantigens, T-Lymphocytes, Tissue Donors, Transplantation Tolerance